Climb Bio (CLYM) Total Liabilities (2020 - 2026)
Climb Bio's (CLYM) quarterly Total Liabilities came in at $4.3 million in Q1 2026, down 41.71% YoY from $7.4 million in Q1 2025, and down 41.02% on a QoQ basis from $7.3 million in Q4 2025.
Climb Bio (CLYM) Total Liabilities (2020 - 2026) Analysis & Trends
Climb Bio (CLYM) has 7 years of Total Liabilities data on file, last reported at $4.3 million in Q1 2026.
- Quarterly Total Liabilities fell 41.71% year-over-year to $4.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.3 million (down 41.71% YoY) and the FY2025 annual result came in at $7.3 million, up 37.0% from the prior year.
- Total Liabilities retreated to $4.3 million in Q1 2026, from $7.3 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $7.9 million in Q2 2022 to a low of $2.9 million in Q4 2023.
- A 5-year average of $5.2 million and a median of $5.3 million in 2025 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2023 — Total Liabilities sank 54.28% — and 2025, when it jumped 149.32%.
- Tracing CLYM's Total Liabilities over 5 years: stood at $6.3 million in 2022, then slumped by 54.28% to $2.9 million in 2023, then soared by 84.88% to $5.3 million in 2024, then soared by 37.0% to $7.3 million in 2025, then sank by 41.02% to $4.3 million in 2026.
- The last three Total Liabilities figures came in at $4.3 million (Q1 2026), $7.3 million (Q4 2025), and $5.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Climb Bio | 1.24 Bn | 1.24 Bn | - | 6.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.75 Mn |
| Mar 31, 2026 | 4.29 Mn |
| Dec 31, 2025 | 7.27 Mn |
| Sep 30, 2025 | 5.30 Mn |
| Jun 30, 2025 | 6.62 Mn |
| Mar 31, 2025 | 7.36 Mn |
| Dec 31, 2024 | 5.31 Mn |
| Sep 30, 2024 | 3.42 Mn |
| Jun 30, 2024 | 3.74 Mn |
| Mar 31, 2024 | 2.95 Mn |
| Dec 31, 2023 | 2.87 Mn |
| Sep 30, 2023 | 2.99 Mn |
| Jun 30, 2023 | 3.77 Mn |
| Mar 31, 2023 | 5.23 Mn |
| Dec 31, 2022 | 6.28 Mn |
| Sep 30, 2022 | 6.50 Mn |
| Jun 30, 2022 | 7.87 Mn |
| Mar 31, 2022 | 7.28 Mn |
| Dec 31, 2021 | 6.04 Mn |
| Sep 30, 2021 | 5.59 Mn |